z-logo
open-access-imgOpen Access
Substantial Depletion of Vicine, Levodopa, and Tyramine in a Fava Bean Protein-Based Nutritional Product
Author(s) -
Paul W. Johns,
Steven R. Hertzler
Publication year - 2021
Publication title -
international journal of food science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.479
H-Index - 18
eISSN - 2356-7015
pISSN - 2314-5765
DOI - 10.1155/2021/6669544
Subject(s) - tyramine , chemistry , levodopa , biochemistry , pharmacology , medicine , disease , parkinson's disease
A commercial fava bean protein isolate and a liquid nutritional product formulated with it were tested by validated HPLC methods for the favism-associated pyrimidine glycoside vicine, the dopamine precursor levodopa, and the biogenic amine tyramine. The vicine, levodopa, and tyramine concentrations in the protein isolate—306, 13.3, and <0.5 mg/kg, respectively—when expressed on a protein basis—34, 1.5, and <0.06 mg/100 g protein, respectively—were at least 96% lower than the vicine, levodopa, and tyramine (protein-based) concentrations reported for fava beans (≥900, ~200, and ~4 mg/100 g protein, respectively). This was also true for the vicine (13 mg/kg or 22 mg/100 g protein), levodopa (≤0.17 mg/kg or ≤0.3 mg/100 g protein), and tyramine (0.08 mg/kg or 0.14 mg/100 g protein) concentrations in the nutritional product. On the basis of these data, one serving (11 fl. oz.) of the nutritional product would deliver approximately 5 mg of vicine, <1 mg of levodopa, and <0.1 mg of tyramine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom